-
Vol 60, June 2022 - current issue
-
Vol 27, September 2019
-
Vol 26, August 2019
-
Vol 25, July 2019
-
Vol 24, June 2019
-
Vol 23, May 2019
-
Vol 22, April 2019
-
Vol 21, March 2019
-
Vol 20, February 2019
-
Vol 19, January 2019
-
Vol 18, December 2018
-
Vol 17, November 2018
-
Vol 16, October 2018
-
Vol 15, September 2018
-
Vol 14, August 2018
-
Vol 13, July 2018
-
Vol 12, June 2018
-
Vol 11, May 2018
-
Vol 10, April 2018
-
Vol 9, March 2018
-
Vol 8, February 2018
-
Vol 7, January 2018
-
Vol 6 No 12, December 2017
-
Vol 6 No 11, November 2017
-
Vol 6 No 10, October 2017
-
Vol 6 No 9, September 2017
-
Vol 6 No 8, August 2017
-
Vol 6 No 7, July 2017
-
Vol 6 No 6, June 2017
-
Vol 6 No 5, May 2017
-
Vol 6 No 4, April 2017
-
Vol 6 No 3, March 2017
-
Vol 6 No 2, February 2017
-
Vol 6 No 1, January 2017
-
Vol 5 No 12, December 2016
-
Vol 5 No 11, November 2016
-
Vol 5 No 10, October 2016
-
Vol 5 No 9, September 2016
-
Vol 5 No 8, August 2016
-
Vol 5 No 7, July 2016
-
Vol 5 No 6, June 2016
-
Vol 5 No 5, May 2016
-
Vol 5 No 4, April 2016
-
Vol 5 No 3, March 2016
-
Vol 5 No 2, February 2016
-
Vol 5 No 1, January 2016
-
Vol 4 No 12, December 2015
-
Vol 4 No 11, November 2015
-
Vol 4 No 10, October 2015
Cover Story Current Issue

Alterations in mitochondrial structure and function are commonly observed in adult-onset neurodegenerative diseases. In ALS, mitochondrial dysfunction impairs the efficiency of electron transport chain (ETC) activity and ATP production and leads to the accumulation of reactive oxygen and nitrogen species, abnormal handling of intracellular calcium and cytochrome C release and apoptosis. The extent to which these alterations in mitochondrial functionimpair cellular operations is unclear. Therapeutic intervention based on combating these mitochondrial abnormalities have displayed variable success in mouse models of ALS and humans, as reviewed in Vandoorne et al.
Sean-Patrick Riechers, Jelena Mojsilovic-Petrovic, Tayler B. Belton, Ram P. Chakrabarty, ... Robert G. Kalb
Current Issue
A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis
- Abstract
A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis
Objective
GALNT2, encoding polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2), was initially discovered as a regulator of high-density lipoprotein metabolism. GalNAc-T2 is known to exert these effects through post-translational modification, i.e., O-linked glycosylationof secreted proteins with established roles in plasma lipid metabolism. It has recently become clear that loss of GALNT2 in rodents, cattle, nonhuman primates, and humans should be regarded as a novel congenital disorder of glycosylation that affects development and body weight. The role of GALNT2 in metabolic abnormalities other than plasma lipids, including insulin sensitivityand energy homeostasis, is poorly understood.
Methods
GWAS data from the UK Biobank was used to study variation in the GALNT2 locus beyond changes in high-density lipoprotein metabolism. Experimental data were obtained through studies in Galnt2−/− mice and wild-type littermates on both control and high-fat diet.
Results
First, we uncovered associations between GALNT2 gene variation, adiposity, and body mass index in humans. In mice, we identify the insulin receptor as a novel substrate of GalNAc-T2 and demonstrate that Galnt2−/− mice exhibit decreased adiposity, alterations in insulin signaling and a shift in energy substrate utilization in the inactive phase.
Conclusions
This study identifies a novel role for GALNT2 in energy homeostasis, and our findings suggest that the local effects of GalNAc-T2 are mediated through posttranslational modification of the insulin receptor.
A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis
- Abstract
A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis
Objective
GALNT2, encoding polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2), was initially discovered as a regulator of high-density lipoprotein metabolism. GalNAc-T2 is known to exert these effects through post-translational modification, i.e., O-linked glycosylationof secreted proteins with established roles in plasma lipid metabolism. It has recently become clear that loss of GALNT2 in rodents, cattle, nonhuman primates, and humans should be regarded as a novel congenital disorder of glycosylation that affects development and body weight. The role of GALNT2 in metabolic abnormalities other than plasma lipids, including insulin sensitivityand energy homeostasis, is poorly understood.
Methods
GWAS data from the UK Biobank was used to study variation in the GALNT2 locus beyond changes in high-density lipoprotein metabolism. Experimental data were obtained through studies in Galnt2−/− mice and wild-type littermates on both control and high-fat diet.
Results
First, we uncovered associations between GALNT2 gene variation, adiposity, and body mass index in humans. In mice, we identify the insulin receptor as a novel substrate of GalNAc-T2 and demonstrate that Galnt2−/− mice exhibit decreased adiposity, alterations in insulin signaling and a shift in energy substrate utilization in the inactive phase.
Conclusions
This study identifies a novel role for GALNT2 in energy homeostasis, and our findings suggest that the local effects of GalNAc-T2 are mediated through posttranslational modification of the insulin receptor.
2021 impact factor: 7.422
The 60 Second Metabolist
In this section authors briefly report on their work recently published in Molecular Metabolism.
Watch the most recent interviews by clicking the video still.
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.